糖尿病患者的慢性肾脏病
Chronic kidney disease in patients with diabetes mellitus.
作者信息
Nordheim Espen, Geir Jenssen Trond
机构信息
Department of Transplantation Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Faculty of Medicine, University of Oslo, Oslo, Norway.
出版信息
Endocr Connect. 2021 Apr 29;10(5):R151-R159. doi: 10.1530/EC-21-0097.
Abstract
Chronic kidney disease is a common complication and concomitant condition of diabetes mellitus. The treatment of patients with diabetes and chronic kidney disease, including intensive control of blood sugar and blood pressure, has been very similar for type 1 and type 2 diabetes patients. New therapeutic targets have shown promising results and may lead to more specific treatment options for patients with type 1 and type 2 diabetes.
摘要
慢性肾脏病是糖尿病常见的并发症和并存疾病。1型和2型糖尿病患者中，糖尿病合并慢性肾脏病患者的治疗，包括强化血糖和血压控制，一直非常相似。新的治疗靶点已显示出有前景的结果，可能会为1型和2型糖尿病患者带来更具针对性的治疗选择。
相似文献
1
Chronic kidney disease in patients with diabetes mellitus.糖尿病患者的慢性肾脏病
Endocr Connect. 2021 Apr 29;10(5):R151-R159. doi: 10.1530/EC-21-0097.
3
Metabolic factors and microinflammatory state promote kidney injury in type 2 diabetes mellitus patients.代谢因素和微炎症状态促进 2 型糖尿病患者的肾脏损伤。
Ren Fail. 2009;31(6):470-4. doi: 10.1080/08860220902963822.
4
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".糖尿病肾病：新的临床和治疗问题。意大利糖尿病学会和意大利肾脏病学会关于“糖尿病肾病的自然病程和肾功能受损的 2 型糖尿病患者的高血糖治疗”的联合立场声明。
Nutr Metab Cardiovasc Dis. 2019 Nov;29(11):1127-1150. doi: 10.1016/j.numecd.2019.07.017. Epub 2019 Oct 2.
5
Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review.1型糖尿病患者的胰岛移植：临床证据综述
Ont Health Technol Assess Ser. 2015 Sep 1;15(16):1-84. eCollection 2015.
6
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.血管紧张素II拮抗作用在2型糖尿病中的作用：肾脏保护研究综述
Clin Ther. 2002 Jul;24(7):1019-34. doi: 10.1016/s0149-2918(02)80016-9.
7
Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.炎症机制作为糖尿病肾病的新型生物标志物和治疗靶点。
Adv Chronic Kidney Dis. 2018 Mar;25(2):181-191. doi: 10.1053/j.ackd.2017.12.002.
8
Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis.与男性相比，糖尿病作为女性发生慢性肾脏病和终末期肾病的危险因素：一项系统评价和荟萃分析。
Endocrine. 2017 Jan;55(1):66-76. doi: 10.1007/s12020-016-1014-6. Epub 2016 Aug 1.
9
Hypertension and diabetes mellitus.高血压和糖尿病
Biomed Pharmacother. 1993;47(2-3):61-6. doi: 10.1016/0753-3322(93)90292-s.
10
Blood pressure lowering for the prevention and treatment of diabetic kidney disease.降低血压以预防和治疗糖尿病肾病。
Drugs. 2006;66(17):2213-34. doi: 10.2165/00003495-200666170-00005.
引用本文的文献
1
A High-Fat Diet Increases Kidney Fibrosis Through Regulating TGF-β and PDGF-β Signaling Pathways in Normotensive and Hypertensive Rat Models.高脂饮食通过调节正常血压和高血压大鼠模型中的TGF-β和PDGF-β信号通路增加肾纤维化。
Int J Mol Sci. 2025 Aug 20;26(16):8031. doi: 10.3390/ijms26168031.
2
Hypoglycaemic Principles of Extracts Reverses Experimental Diabetes and Diabetes Associated Pathology in Wistar Albino Rats.提取物的降血糖原理可逆转Wistar白化大鼠的实验性糖尿病及糖尿病相关病理变化。
Biochem Res Int. 2025 Jul 31;2025:7173019. doi: 10.1155/bri/7173019. eCollection 2025.
3
Dissecting the relationship between heart failure and diabetic retinopathy severity in patients with diabetes and chronic kidney disease: an observational cohort study.剖析糖尿病合并慢性肾脏病患者心力衰竭与糖尿病视网膜病变严重程度之间的关系：一项观察性队列研究
Sci Rep. 2025 Jul 8;15(1):24346. doi: 10.1038/s41598-025-04523-1.
4
Coming of age: could obesity-related metabolic complications be treated by targeting senescent cells?成年：能否通过靶向衰老细胞来治疗肥胖相关的代谢并发症？
Front Cell Dev Biol. 2025 Jun 4;13:1622107. doi: 10.3389/fcell.2025.1622107. eCollection 2025.
5
A Nationwide Epidemiological Study of Chronic Kidney Disease Prevalence in a High-Risk Patient Population Without Prior Diagnosis in Primary Health Care in Poland.波兰一项针对初级卫生保健中未预先诊断的高危患者群体慢性肾病患病率的全国性流行病学研究。
J Clin Med. 2025 May 21;14(10):3600. doi: 10.3390/jcm14103600.
6
Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease.来自土耳其的真实世界见解：生物性改善病情抗风湿药在慢性肾脏病脊柱关节炎患者中的应用
Int J Rheum Dis. 2025 May;28(5):e70274. doi: 10.1111/1756-185X.70274.
7
The safety of indocyanine green in patients with advanced chronic kidney disease or kidney transplantation: a scoping review.吲哚菁绿在晚期慢性肾病或肾移植患者中的安全性：一项范围综述。
Ann Med Surg (Lond). 2024 Nov 18;87(3):1351-1359. doi: 10.1097/MS9.0000000000002713. eCollection 2025 Mar.
8
From fat to filter: the effect of adipose tissue-derived signals on kidney function.从脂肪到滤过器：脂肪组织衍生信号对肾功能的影响。
Nat Rev Nephrol. 2025 Apr 2. doi: 10.1038/s41581-025-00950-5.
9
Prevalence of chronic kidney disease in Saudi Arabia: an epidemiological population-based study.沙特阿拉伯慢性肾脏病的患病率：一项基于人群的流行病学研究。
BMC Nephrol. 2025 Jan 24;26(1):37. doi: 10.1186/s12882-025-03954-2.
10
Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review.胰高血糖素样肽-1受体激动剂介导的体重减轻及糖尿病获益：一项叙述性综述
Cureus. 2024 Dec 20;16(12):e76101. doi: 10.7759/cureus.76101. eCollection 2024 Dec.
本文引用的文献
1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
2
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m: Subgroup Analysis of the Randomized CREDENCE Trial.基线 eGFR<30 ml/min/1.73 m2 的患者中卡格列净的疗效：随机 CREDENCE 试验的亚组分析。
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19.
3
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2020慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
4
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
5
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.在 2 型糖尿病患者中使用依格列净的心血管结局。
N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
7
Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.磺达肝癸钠对 2 型糖尿病非肾病范围蛋白尿患者的肾脏作用。
J Diabetes Res. 2020 Aug 8;2020:2984680. doi: 10.1155/2020/2984680. eCollection 2020.
8
Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results.2型糖尿病患者肾活检作用的见解：全球肾活检结果的文献综述
Diabetes Ther. 2020 Sep;11(9):1983-1999. doi: 10.1007/s13300-020-00888-w. Epub 2020 Aug 5.
9
Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis.将尿蛋白肌酐比或尿试纸条蛋白转化为尿白蛋白肌酐比用于慢性肾脏病筛查和预后的研究：一项基于个体参与者的荟萃分析。
Ann Intern Med. 2020 Sep 15;173(6):426-435. doi: 10.7326/M20-0529. Epub 2020 Jul 14.
10
Bardoxolone methyl: drug development for diabetic kidney disease.巴多索隆甲基：用于治疗糖尿病肾病的药物研发。
Clin Exp Nephrol. 2020 Oct;24(10):857-864. doi: 10.1007/s10157-020-01917-5. Epub 2020 Jun 27.
Zotero 插件